Variation of circulating tumor cell levels during treatment of metastatic breast cancer: Prognostic and therapeutic implications

Research output: Contribution to journalArticle

Abstract

Background: This study aimed to evaluate the prognostic significance of circulating tumor cells (CTCs) detection in advanced breast cancer patients. Patients and methods: We tested 80 patients for CTC levels before starting a new treatment and after 4, 8 weeks, at the first clinical evaluation and every 2 months thereafter. CTCs were detected using the CellSearch System™. Results: Forty-nine patients had ≥5 CTCs at baseline. At the multivariate analysis, baseline number of CTCs was significantly associated with progression-free survival [hazard ratio (HR) 2.5; 95% confidence interval (CI) 1.2-5.4]. The risk of progression for patients with CTCs ≥5 at last available blood draw was five times the risk of patients with 0-4 CTCs at the same time point (HR 5.3; 95% CI 2.8-10.4). Patients with rising or persistent ≥5 CTCs at last available blood draw showed a statistically significant higher risk of progression with respect to patients with

Original languageEnglish
Pages (from-to)891-897
Number of pages7
JournalAnnals of Oncology
Volume19
Issue number5
DOIs
Publication statusPublished - May 2008

Keywords

  • Advanced breast cancer
  • Breast cancer
  • Circulating tumor cells
  • Novel assay technology
  • Prognostic value
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Variation of circulating tumor cell levels during treatment of metastatic breast cancer: Prognostic and therapeutic implications'. Together they form a unique fingerprint.

  • Cite this